Press releases

ORYZON reports financial results and corporate update for quarter ended December 31, 2024

ORYZON announces journal publication of final Phase IIa REIMAGINE results with vafidemstat in Psychiatry and Clinical Neurosciences

ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting

ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome

ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor

ORYZON announces first patient dosed in NCI-sponsored iadademstat in combination with venetoclax and azacitidine clinical trial in first line acute myeloid leukemia

ORYZON to provide corporate progress updates at several events in January-February

ORYZON continues to strengthen its patent portfolio for vafidemstat

ORYZON receives Notice of allowance for patent on novel technology for measuring LSD1 target engagement

ORYZON reports financial results and corporate update for quarter ended September 30, 2024